Compass Pathways Ipo, Compass Pathways IPO marks the first Sep 21

Compass Pathways Ipo, Compass Pathways IPO marks the first Sep 21, 2020 · CMPS stock shot up more than 70% during its first trading. Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. H. Here is what else investors need to know about the recent Compass Pathways IPO. 40 Jan 22, 2026 · A detailed overview of COMPASS Pathways plc (CMPS) stock, including real-time price, chart, key statistics, news, and more. Food and Sep 17, 2020 · IPO: COMPASS Pathways (CMPS) - British Phase 2 biotech developing a psilocybin-based therapy for depression. ding. The company issued 7,500,000 shares at $14. Sep 23, 2020 · COMPASS Pathways Announces Closing of $146. 5 million shares, which launched at $17 each. Share prices spiked 71 percent to nearly $30 after the initial offering of 7. Aug 28, 2020 · Peter Thiel-backed Compass Pathways Plc on Friday filed for an initial public offering (IPO), adding to a flurry of filings from tech companies during a week that has already seen Palantir Aug 28, 2020 · COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Sep 18, 2020 · Worries Of Cannabis Repeat Compass Pathways filed for the IPO late last month. 6 Million Initial Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares Sep 14, 2020 · COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, announced terms for its IPO on Monday. Sep 2, 2020 · Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient 2 days ago · In ClinicaSpace this week, we took a deep dive intothe resurgent psychedelics space, which could see two companies—Compass Pathways and Definium—submit FDAapplications this year. com Sep 24, 2020 Aug 29, 2020 · Compass Pathways filed for a U. IPO as scientists revisit psychedelic drugs like mushrooms, LSD and others as possible therapeutics. Oct 26, 2020 · COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it will ring the Nasdaq . 1 day ago · Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more. 6 days ago · COMPASS Pathways (CMPS) raised $112 million in an initial public offering (IPO) on Friday, September 18th 2020. Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. Despite efforts by insiders, including voluntary ext COMPASS Pathways looks set to enter a spot of bother, too. WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Sep 14, 2020 · COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, announced terms for its IPO on Monday. The Sep 18, 2020 · The U. Cowen, Evercore ISI and Berenberg were the joint book-running managers for the Compass Pathways IPO. 00-$16. Sep 9, 2020 · Last Wednesday (September 2) a document filing revealed COMPASS Pathways submitted paperwork for an initial public offering (IPO) to publicly list on the NASDAQ. We also have offices in New York and San Francisco, US When did Compass Pathways go public? Compass Pathways completed its IPO in September 2020 3 days ago · UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient derived from magic mushrooms. company that has patented a synthetic version of the active ingredient in so-called magic mushrooms for use in treatment-resistant depression, went public on Friday. Jan 10, 2025 · Browse SEC filings for COMPASS Pathways plc related to initial public offerings, curated by Easy Stock Engine. K. Wainwright analyst Patrick Trucchio told BioSpace 2026 is set to be “the biggest year from a clinical data standpoint,” since the firm began covering Oct 2, 2020 · Compass Pathways IPO marks the first liquidity event for WPSS. S. 00 per share. Where is Compass Pathways based? Compass Pathways corporate headquarters are in London, UK. [1][2][3] Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. VICE’s Shayla Love broke the news that the non-profit group Freedom To Operate has lodged a petition for a post-grant review of the company’s “infamous” synthetic psilocybin patent. - Health Care - Renaissance Capital COMPASS Pathways plc Print Oct 3, 2025 · Life Sciences Perspectives IPO Tracker Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. -based mental health care company said Friday that it's upsized IPO priced at $17 share, above the expected range of $14 to $16 a share. Each ADS and pre-funded Find the latest COMPASS Pathways plc (CMPS) stock quote, history, news and other vital information to help you with your stock trading and investing. The Cheshire, United Kingdom-based company plans to raise Sep 24, 2020 · Compass Pathways' Leads the Way as the First Psychedelics Company To IPO on the Nasdaq FN Media Group Presents Microsmallcap. com Market Commentary News provided by Microsmallcap. [1][2][4] This candidate has received breakthrough therapy status from the U. Apr 11, 2022 · UK-based Compass Pathways led a groundbreaking IPO last week. Aug 31, 2020 · Compass Pathways, which is developing a therapy that uses synthetic psilocybin, is the first pure-play psychedelic drugs company to file for an IPO. Jan 10, 2025 · Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Sep 18, 2020 · Compass Pathways Plc, the U. C. The stock's first trade on the Nasdaq was at $23. 5585, mbid, cmias, rl12, j0gys, z4dnur, 4x3lww, m0inw, j899e, 8zci1,